Journal
TRENDS IN CARDIOVASCULAR MEDICINE
Volume 11, Issue 8, Pages 339-344Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/S1050-1738(01)00133-5
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL-48743, HL-34836, HL-52233] Funding Source: Medline
- NINDS NIH HHS [NS-10828] Funding Source: Medline
Ask authors/readers for more resources
Salicylates are effective prophylactic treatment strategies for myocardial infarction and ischemic strokes. Recent evidence suggests that high doses of salicylates may exert direct, platelet-independent effects on the vascular wall. Salicylate and aspirin, in concentrations between 1 and 5 mM, effectively inhibit vascular smooth muscle cell proliferation and DNA synthesis without inducing cellular toxicity or apoptosis. This inhibition is associated with effects on specific cell-cycle regulatory molecules, and may proceed via downregulation of the transcription factor; nuclear factor (NF)-kappaB. High-dose salicylates and selective NF-kappaB inhibitors may, therefore, play an important role in the management of vascular proliferative disorders. (C) 2001, Elsevier Science Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available